-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $112

Benzinga·04/28/2026 11:19:53
Listen to the news
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $95 to $112.